Cochlear is a medical devices business based in Australia. Cochlear shares (COH) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Cochlear has a trailing 12-month revenue of around $2.1 billion. If you're looking to buy shares, check out the steps below.
To buy shares listed in Australia such as Cochlear, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.
Our top pick for
Best for day trading
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $227.0864 - $348.0457 |
|---|---|
| 50-day moving average | $325.3196 |
| 200-day moving average | $306.9056 |
| Target price | $283.61 |
| PE ratio | 60.9793 |
| Dividend yield | $3.75 (1.24%) |
| Earnings per share (TTM) | $5.31 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$328.44
| 1 week (2024-07-16) | -1.62% |
|---|---|
| 1 month (2024-06-21) | 1.03% |
| 3 months (2024-04-23) | 1.72% |
| 6 months (2024-01-23) | 8.76% |
| 1 year (2023-07-21) | 40.44% |
|---|---|
| 2 years (2022-07-22) | 53.48% |
| 3 years (2021-07-23) | 33.47% |
| 5 years (2019-07-23) | 49.73% |
Valuing Cochlear stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cochlear's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cochlear's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 61x. In other words, Cochlear shares trade at around 61x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cochlear's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $519.1 million (£266 million).
The EBITDA is a measure of a Cochlear's overall financial performance and is widely used to measure stock profitability.
| Revenue TTM | $2.1 billion |
|---|---|
| Operating margin TTM | 23.57% |
| Gross profit TTM | $1.4 billion |
| Return on assets TTM | 11.8% |
| Return on equity TTM | 20.04% |
| Profit margin | 16.3% |
| Book value | 27.17 |
| Market capitalisation | $21.2 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Cochlear.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 24.39
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Cochlear's overall score of 24.39 (as at 12/31/2018) is nothing to write home about – landing it in it in the 45th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Cochlear is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.73/100
Cochlear's environmental score of 3.73 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Cochlear is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14.34/100
Cochlear's social score of 14.34 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Cochlear is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 10.32/100
Cochlear's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Cochlear is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Cochlear scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Cochlear has, for the most part, managed to keep its nose clean.
Cochlear Ltd was last rated for ESG on: 2019-01-01.
| Total ESG score | 24.39 |
|---|---|
| Total ESG percentile | 44.88 |
| Environmental score | 3.73 |
| Environmental score percentile | 2 |
| Social score | 14.34 |
| Social score percentile | 2 |
| Governance score | 10.32 |
| Governance score percentile | 2 |
| Level of controversy | 2 |
Dividend payout ratio: 62.02% of net profits
Recently Cochlear has paid out, on average, around 62.02% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.24% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Cochlear shareholders could enjoy a 1.24% return on their shares, in the form of dividend payments. In Cochlear's case, that would currently equate to about A$3.75 per share.
Cochlear's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 20 March 2024 (the "ex-dividend date").
Over the last 12 months, Cochlear's shares have ranged in value from as little as $227.0864 up to $348.0457. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Cochlear's is 0.485. This would suggest that Cochlear's shares are less volatile than average (for this exchange).
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Consider these benefits and drawbacks before you invest in uranium stocks.
What to know before investing in this young but rapidly growing industry that protects against cybercrimes.
CommSec Pocket and Raiz Invest both micro-invest into the stock market, so what are the differences and why should you pick one over the other?
Learn what an initial public offering (IPO) is, how an IPO works and the advantages and risks of IPOs.
If you’re thinking of investing in gold, our guide will explain how and where to buy gold in Australia as well as the pros and cons of investing in it.
Here's a guide to your different investment options, the benefits of investing in silver and the possible risks.
Join the world’s largest social trading network and learn from experienced forex traders with eToro Australia.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.